Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 175

1.

Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer.

Lustberg MB, Povoski SP, Zhao W, Ziegler RM, Sugimoto Y, Ruppert AS, Lehman AM, Shiels DR, Mrozek E, Ramaswamy B, Layman RM, Brueggemeier RW, Shapiro CL.

Clin Breast Cancer. 2011 Aug;11(4):221-7. doi: 10.1016/j.clbc.2011.03.022. Epub 2011 May 19.

2.

Bone metabolism and quality-of-life of postmenopausal women with invasive breast cancer receiving neoadjuvant hormonal therapy: sub-analyses from celecoxib anti-aromatase neoadjuvant (CAAN) trial.

Chow LW, Yip AY, Chu WP, Loo WT, Toi M.

J Steroid Biochem Mol Biol. 2011 May;125(1-2):112-9. doi: 10.1016/j.jsbmb.2010.12.018. Epub 2011 Jan 12.

PMID:
21236344
3.

Pre-surgical study of the biological effects of the selective cyclo-oxygenase-2 inhibitor celecoxib in patients with primary breast cancer.

Martin LA, Davies GL, Weigel MT, Betambeau N, Hills MJ, Salter J, Walsh G, A'Hern R, Dowsett M.

Breast Cancer Res Treat. 2010 Oct;123(3):829-36. doi: 10.1007/s10549-010-1100-z. Epub 2010 Aug 10.

PMID:
20697803
4.

Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study.

Falandry C, Debled M, Bachelot T, Delozier T, Crétin J, Romestaing P, Mille D, You B, Mauriac L, Pujade-Lauraine E, Freyer G.

Breast Cancer Res Treat. 2009 Aug;116(3):501-8. doi: 10.1007/s10549-008-0229-5. Epub 2008 Nov 20.

PMID:
19020973
5.
7.

Multicenter phase II trial of neoadjuvant exemestane for postmenopausal patients with hormone receptor-positive, operable breast cancer: Saitama Breast Cancer Clinical Study Group (SBCCSG-03).

Takei H, Suemasu K, Inoue K, Saito T, Okubo K, Koh J, Sato K, Tsuda H, Kurosumi M, Tabei T; Saitama Breast Cancer Clinical Study Group.

Breast Cancer Res Treat. 2008 Jan;107(1):87-94. Epub 2007 Feb 15.

PMID:
18043897
8.

Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17).

Mlineritsch B, Tausch C, Singer C, Luschin-Ebengreuth G, Jakesz R, Ploner F, Stierer M, Melbinger E, Menzel C, Urbania A, Fridrik M, Steger G, Wohlmuth P, Gnant M, Greil R; Austrian Breast, Colorectal Cancer Study Group (ABCSG).

Breast Cancer Res Treat. 2008 Nov;112(1):203-13. Epub 2007 Dec 22.

PMID:
18158620
9.

Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial.

Bundred NJ, Cramer A, Morris J, Renshaw L, Cheung KL, Flint P, Johnson R, Young O, Landberg G, Grassby S, Turner L, Baildam A, Barr L, Dixon JM.

Clin Cancer Res. 2010 Mar 1;16(5):1605-12. doi: 10.1158/1078-0432.CCR-09-1623. Epub 2010 Feb 23.

10.

Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer.

Chow LW, Yip AY, Loo WT, Lam CK, Toi M.

J Steroid Biochem Mol Biol. 2008 Jul;111(1-2):13-7. doi: 10.1016/j.jsbmb.2008.04.004. Epub 2008 Apr 20.

PMID:
18514508
11.

Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition.

Toi M, Saji S, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Takada M, Ueno T, Saji S, Chanplakorn N, Suzuki T, Sasano H.

Cancer Sci. 2011 Apr;102(4):858-65. doi: 10.1111/j.1349-7006.2011.01867.x. Epub 2011 Feb 10.

12.
13.

Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.

Duman BB, Afşar ÇU, Günaldi M, Sahin B, Kara IO, Erkisi M, Erçolak V.

Asian Pac J Cancer Prev. 2012;13(8):4119-23.

14.

Exemestane as neoadjuvant hormonotherapy for locally advanced breast cancer: results of a phase II trial.

Tubiana-Hulin M, Becette V, Bieche I, Mauriac L, Romieu G, Bibeau F, Macgrogan G, Bourgeois H, Chollet P, Defrance R, Spyratos F.

Anticancer Res. 2007 Jul-Aug;27(4C):2689-96.

15.

Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.

Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M, Fein L, Romieu G, Buzdar A, Robertson JF, Brufsky A, Possinger K, Rennie P, Sapunar F, Lowe E, Piccart M.

J Clin Oncol. 2008 Apr 1;26(10):1664-70. doi: 10.1200/JCO.2007.13.5822. Epub 2008 Mar 3.

16.

Endocrine and clinical endpoints of exemestane as neoadjuvant therapy.

Miller WR, Dixon JM.

Cancer Control. 2002 Mar-Apr;9(2 Suppl):9-15. Review.

PMID:
11965226
17.

COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment.

Generali D, Buffa FM, Deb S, Cummings M, Reid LE, Taylor M, Andreis D, Allevi G, Ferrero G, Byrne D, Martinotti M, Bottini A, Harris AL, Lakhani SR, Fox SB.

Br J Cancer. 2014 Jul 8;111(1):46-54. doi: 10.1038/bjc.2014.236. Epub 2014 May 29.

18.

[Effect of neoadjuvant chemotherapy on histologic grade and expression of biological markers in breast cancer].

Yin HF, Wang YH, Qin XQ, Zhang H, Li T, Ye JM, Liu YH.

Zhonghua Zhong Liu Za Zhi. 2009 Nov;31(11):858-62. Chinese.

PMID:
20137353
19.

Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: preliminary report.

Chow LW, Wong JL, Toi M.

J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):443-7.

PMID:
14623542
20.

Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group.

Paridaens RJ, Dirix LY, Beex LV, Nooij M, Cameron DA, Cufer T, Piccart MJ, Bogaerts J, Therasse P.

J Clin Oncol. 2008 Oct 20;26(30):4883-90. doi: 10.1200/JCO.2007.14.4659. Epub 2008 Sep 15.

Items per page

Supplemental Content

Write to the Help Desk